Free Trial
OTCMKTS:ELTP

Elite Pharmaceuticals (ELTP) Stock Price, News & Analysis

Elite Pharmaceuticals logo
$0.54 0.00 (0.00%)
As of 05/30/2025 03:59 PM Eastern

About Elite Pharmaceuticals Stock (OTCMKTS:ELTP)

Key Stats

Today's Range
$0.53
$0.54
50-Day Range
$0.32
$0.54
52-Week Range
$0.16
$0.75
Volume
454,102 shs
Average Volume
921,231 shs
Market Capitalization
$575.85 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Elite Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development, manufacture, and sale of oral, controlled-release products, and generic pharmaceuticals. The company operates in two segments, Abbreviated New Drug Applications for Generic Pharmaceuticals and New Drug Applications for Branded Pharmaceuticals. It owns, licenses, manufactures, and sells various generic and oral dose pharmaceuticals products, such as Phentermine HCl 37.5mg tablets, and 15mg and 30mg capsules for the treatment of bariatrics under Adipex-P brand; Phendimetrazine Tartrate 35mg tablets for bariatrics under the Bontril brand; Naltrexone HCl 50mg tablets for the treatment of pains under the Revia brand; and Isradipine 2.5mg and 5mg capsules for cardiovascular diseases. The company also provides Trimipramine Maleate Immediate Release antidepressant capsules under the Surmontil brand; Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate, and Amphetamine Sulfate Immediate Release tablets under the Adderall brand, as well as Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate, Amphetamine Sulfate Extended Release capsules under the Adderall XR brand for central nervous system diseases; Dantrolene Sodium capsules for muscle relaxant under the Dantrium brand; SequestOX, an immediate release Oxycodone with Naltrexone; Loxapine Succinate capsules for treating antipsychotic under the Loxapine brand; Acetaminophen and Codeine Phosphate for the management of mild to moderate pain; and antibiotic products. In addition, it manufactures controlled-release products on a contract basis for third parties in the areas of pain, allergy, bariatric, attention deficit, and infection. Further, the company is developing a range of abuse deterrent opioid products. Elite Pharmaceuticals, Inc. was incorporated in 1997 and is headquartered in Northvale, New Jersey.

Receive ELTP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Elite Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ELTP Stock News Headlines

Elite Pharmaceuticals Gains FDA Approval for Generic Vyvanse
"I'm risking my reputation on this"
Behind closed doors, away from the mainstream media's eyes, the smartest minds in crypto are all seeing the same signals. They're positioning themselves for something unprecedented. And after 17 million podcast downloads and over 600 insider interviews, I finally connected all the dots… What I discovered was so explosive, so potentially life-changing, that I had to put it all in a book.
Elite Pharmaceuticals Reports Strong Q2 2025 Financial Results
See More Headlines

ELTP Stock Analysis - Frequently Asked Questions

Elite Pharmaceuticals' stock was trading at $0.5411 on January 1st, 2025. Since then, ELTP stock has decreased by 0.4% and is now trading at $0.5390.
View the best growth stocks for 2025 here
.

Elite Pharmaceuticals, Inc. (OTCMKTS:ELTP) announced its earnings results on Thursday, February, 13th. The specialty pharmaceutical company reported ($0.01) earnings per share (EPS) for the quarter. Elite Pharmaceuticals had a negative net margin of 25.70% and a negative trailing twelve-month return on equity of 6.92%.
Read the conference call transcript
.

Shares of ELTP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Elite Pharmaceuticals investors own include Research Frontiers (REFR), Co-Diagnostics (CODX), Novavax (NVAX), FuelCell Energy (FCEL), Onconova Therapeutics (ONTX), iBio (IBIO) and Inovio Pharmaceuticals (INO).

Company Calendar

Last Earnings
2/13/2025
Today
6/01/2025
Next Earnings (Estimated)
6/30/2025
Fiscal Year End
3/31/2026

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
OTCMKTS:ELTP
Employees
40
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$20.11 million
Pretax Margin
-24.76%

Debt

Sales & Book Value

Annual Sales
$56.62 million
Cash Flow
$0.03 per share
Price / Cash Flow
16.94
Book Value
$0.03 per share
Price / Book
17.97

Miscellaneous

Outstanding Shares
1,068,363,000
Free Float
914,305,000
Market Cap
$575.85 million
Optionable
Not Optionable
Beta
0.04
20 Stocks to Sell Now Cover

Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.

Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.

Get This Free Report

This page (OTCMKTS:ELTP) was last updated on 6/1/2025 by MarketBeat.com Staff
From Our Partners